Dr Braun on Frontline Nivolumab Monotherapy Followed by Salvage Nivolumab/Ipilimumab in RCCApril 10th 2023
David A. Braun, MD, PhD, discusses the rationale for evaluating frontline nivolumab and salvage nivolumab plus ipilimumab in patients with advanced renal cell carcinoma in the phase 2 HCRN GU16-260 trial.
Dr. Braun on Frontline Immunotherapy in Advanced RCCFebruary 7th 2020
David A. Braun, MD, PhD, physician at Dana-Farber Cancer Institute and instructor of medicine at Harvard Medical School, discusses the use of immunotherapy in the frontline treatment of patients with advanced renal cell carcinoma (RCC).
New Perioperative Strategies Emerge for High-Risk, Resectable RCCDecember 4th 2019
The current management of metastatic renal cell carcinoma reflects the progress of medical oncology throughout the past several decades. The standard of care has evolved from cytokine-based therapies to targeted molecular therapies and immune checkpoint inhibitor–based strategies.